Switching to NOACs in frail elderly patients with atrial fibrillation increases bleeding risk

Ot­su­ka Phar­ma­ceu­ti­cal is boost­ing a long-run­ning men­tal health pro­gram with a dig­i­tal re­launch, open­ing broad­er avail­abil­i­ty for the free re­source. Called WILD 5, now spon­sored

Ar­cus Bio­sciences is re­duc­ing fur­ther in­vest­ment on its adeno­sine re­cep­tor an­tag­o­nist in prostate can­cer af­ter re­view­ing in­ter­im da­ta, ac­cord­ing to its sec­ond quar­ter re­port. In